Myasthenia gravis: newer therapies offer sustained improvement
- PMID: 24186889
- DOI: 10.3949/ccjm.80a.13044
Myasthenia gravis: newer therapies offer sustained improvement
Abstract
Myasthenia gravis is a prototypical antibody-mediated autoimmune neuromuscular disorder. Treatments have improved over the past 30 years, leading to significantly fewer deaths and better quality of life. Future research should further elucidate its pathogenesis, reveal better ways to diagnose it, and yield new treatments.
Comment in
-
Myasthenia gravis (NOVEMBER 2013).Cleve Clin J Med. 2014 Mar;81(3):144-5. doi: 10.3949/ccjm.81c.03003. Cleve Clin J Med. 2014. PMID: 24591468 No abstract available.
-
In reply.Cleve Clin J Med. 2014 Mar;81(3):145. doi: 10.3949/ccjm.81c.03004. Cleve Clin J Med. 2014. PMID: 24591469 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous